MedTrace Logo

Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

NCT06448962 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2024-06-07

No results posted yet for this study

Summary

The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Conditions

  • Hypertension, Essential
  • Primary Hypercholesterolemia

Interventions

DRUG

AD-2021

PO, Once daily(QD), 8weeks

DRUG

AD-2022

PO, Once daily(QD), 8weeks

DRUG

AD-2021 Placebo

PO, Once daily(QD), 8weeks

DRUG

AD-2022 Placebo

PO, Once daily(QD), 8weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Seok Min Kang, M.D., Ph.D · Yonsei Cardiovascular Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-22
Primary Completion
2021-11-22
Completion
2021-11-22

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06448962 on ClinicalTrials.gov